Kancera AB (publ) hereby reports results from a Phase I study in healthy subjects with the immunoregulating drug candidate KAND567. The study shows that KAND567 is safe and well-tolerated up to 500 mg twice daily for 7 days. The...
Read MoreKancera AB (publ) reports that the Phase I study in the Fractalkine project has been completed in accordance with study protocols. In the study, drug characteristics, safety and tolerability have been documented for KAND567 in 62 healthy subjects. The...
Read MoreKancera AB (publ) has previously announced that the company controls patents and rights to the Fractalkine project, including KAND567, in all diseases except lung diseases. Agreements with AstraZeneca AB and Acturum Real Estate AB now give Kancera AB full...
Read MoreAccording to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore,...
Read MoreKancera hereby reports that the company's ROR inhibitor KAN0441571 effectively eliminates ROR1-bearing leukemic cells in a mouse model of human chronic lymphocytic leukemia.
Read MoreKancera, a development company focused on cancer therapy and Recipharm, a leading contract development and manufacturing organisation (CDMO), have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567.
Read MoreKancera today launches the second part of the ongoing clinical Phase I study of KAND567. During this part of the study, KAND567 is administered to groups of healthy subjects in increasing doses, twice a day for seven days. The...
Read MoreThe Medical Ethics Committee (METC) at the University Medical Center in Groningen, The Netherlands, has approved the start of clinical Phase I study of KAND567. The first dose to humans will be given within the next few weeks.
Read MoreKancera AB has applied for approval for a Phase I clinical trial. The study is planned to be conducted in collaboration with the clinical contract company QPS in Groningen, The Netherlands.
Read MoreKancera reports that PFKFB3-inhibitor KAN0438757 increases the effect of a promising class of drugs for intractable cancer. Kancera has strengthened their development of drugs directed against PFKFB3 and DNA repair through a new recruitment. The European and US patent...
Read More